Skip to Main Content
Table 6.2

Standardized CGM metrics for clinical care

1. Number of days CGM device is worn (recommend 14 days)  
2. Percentage of time CGM device is active (recommend 70% of data from 14 days)  
3. Mean glucose  
4. Glucose management indicator  
5. Glycemic variability (%CV) target ≤36%*  
6. TAR: % of readings and time >250 mg/dL (>13.9 mmol/L) Level 2 hyperglycemia 
7. TAR: % of readings and time 181–250 mg/dL (10.1–13.9 mmol/L) Level 1 hyperglycemia 
8. TIR: % of readings and time 70–180 mg/dL (3.9–10.0 mmol/L) In range 
9. TBR: % of readings and time 54–69 mg/dL (3.0–3.8 mmol/L) Level 1 hypoglycemia 
10. TBR: % of readings and time <54 mg/dL (<3.0 mmol/L) Level 2 hypoglycemia 
1. Number of days CGM device is worn (recommend 14 days)  
2. Percentage of time CGM device is active (recommend 70% of data from 14 days)  
3. Mean glucose  
4. Glucose management indicator  
5. Glycemic variability (%CV) target ≤36%*  
6. TAR: % of readings and time >250 mg/dL (>13.9 mmol/L) Level 2 hyperglycemia 
7. TAR: % of readings and time 181–250 mg/dL (10.1–13.9 mmol/L) Level 1 hyperglycemia 
8. TIR: % of readings and time 70–180 mg/dL (3.9–10.0 mmol/L) In range 
9. TBR: % of readings and time 54–69 mg/dL (3.0–3.8 mmol/L) Level 1 hypoglycemia 
10. TBR: % of readings and time <54 mg/dL (<3.0 mmol/L) Level 2 hypoglycemia 

CGM, continuous glucose monitoring; CV, coefficient of variation; TAR, time above range; TBR, time below range; TIR, time in range.

*

Some studies suggest that lower %CV targets (<33%) provide additional protection against hypoglycemia for those receiving insulin or sulfonylureas. Adapted from Battelino et al. (34).

Close Modal

or Create an Account

Close Modal
Close Modal